P3 Health (PIII) Q3 2026 Earnings Call Transcript
P3 Health (PIII) reported Q3 2026 Adjusted EBITDA of $21M, raising full-year guidance to $90M-$100M. CEO Aric Coffman highlighted medical cost management, quality improvements, and growth strategies. The company is expanding in existing markets and entering new ones, like Nebraska, with a capital-efficient approach.
How this was made
The 30-second read
Why it matters
The guidance increase signals better cost management and growth execution, which could prompt buying pressure.
Market read
Guidance lift is the primary new information, offering a clear trading catalyst for PIII.
What to watch
Potential headwinds from regulatory changes or payer contract renewals are not addressed in the call.
Background
P3 Health Partners (PIII) delivered its Q3 2026 earnings call, highlighting $21 million Adjusted EBITDA for the quarter and raising full‑year guidance.
Ticker impact
P3 Health Partners raised its full‑year Adjusted EBITDA guidance to a $90‑$100 million range in its Q3 2026 earnings call.
likely upward pressure as investors price in higher earnings outlook
The company disclosed new, higher guidance for the first time, a material update that can move the stock.
Market effects
Improved outlook for the Medicare Advantage and health‑services sector may lift peers.
U.S. health‑care stocks could see modest gains.
Limited to U.S. health‑care investors.
Counterpoint
If the guidance raise is already priced in, the stock may face a short‑term pullback.
Key entities
- ExecutiveAric Coffman
CEO of P3 Health Partners who presented the earnings results.
- ExecutiveWilliam Hoover
Head of Investor Relations who opened the call.
